<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease - Health AI Hub</title>
    <meta name="description" content="This paper proposes a systemic pathological network model for Alzheimer's disease (AD), emphasizing the intricate cross-talk between amyloid-$Œ≤$ (A$Œ≤$), tau, an">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04937v1" target="_blank">2512.04937v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-04
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> She Xutong
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.MN
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04937v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04937v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper proposes a systemic pathological network model for Alzheimer's disease (AD), emphasizing the intricate cross-talk between amyloid-$Œ≤$ (A$Œ≤$), tau, and neuroinflammation. It critically analyzes the modest efficacy of current single-target therapies, advocating for a shift towards biomarker-guided, personalized combination interventions to fundamentally alter AD's disease trajectory.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This analysis is highly relevant for medical professionals and researchers as it shifts the conceptual understanding of Alzheimer's disease towards a multi-factorial network, paving the way for more effective, integrated diagnostic tools and personalized combination therapies that could significantly improve patient outcomes and disease management.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The abstract explicitly states 'AI-driven patient stratification' as an integral part of the promising roadmap toward altering the trajectory of Alzheimer's disease, indicating AI's role in personalizing treatment and management strategies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>AD pathogenesis is re-conceptualized from a linear amyloid cascade to a complex network of interacting pathologies, encompassing A$Œ≤$, tau, and neuroinflammation, forming a phase-adapted pathological network model.</li>
                    
                    <li>Diagnostic paradigms have evolved to utilize biomarker-based strategies, such as the AT(N) framework, enabling early detection during preclinical or prodromal AD stages.</li>
                    
                    <li>Current disease-modifying therapies, like anti-A$Œ≤$ monoclonal antibodies (e.g., lecanemab, donanemab), represent breakthroughs but exhibit modest efficacy, underscoring the limitations of single-target approaches.</li>
                    
                    <li>A compelling rationale is presented for combination therapies that simultaneously target multiple core AD pathologies: A$Œ≤$, aberrant tau, and neuroinflammation.</li>
                    
                    <li>The paper emphasizes the integration of early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification for advancing precision medicine in AD.</li>
                    
                    <li>Emerging technological platforms, including gene editing and biophysical neuromodulation, are highlighted as crucial for future therapeutic development.</li>
                    
                    <li>The ultimate vision for AD management involves preemptive, biomarker-guided, and personalized combination interventions aimed at fundamentally altering the disease course.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>This paper is a comprehensive review and synthesis of the evolving understanding of Alzheimer's disease pathogenesis, diagnostic paradigms, and therapeutic strategies. It employs a conceptual modeling approach to propose a systemic pathological network model and rationalizes combinatorial intervention strategies based on current clinical outcomes and emerging technologies.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary 'findings' are conceptual and strategic rather than experimental data. They include: AD pathogenesis is best described as an intricate, interacting network of A$Œ≤$, tau, and neuroinflammation; current single-target AD therapies have modest efficacy, necessitating a shift; combination therapies simultaneously targeting multiple core pathologies are rationally compelling; and early, biomarker-guided detection is critical for effective intervention.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This work has potential clinical impact by promoting earlier, biomarker-guided diagnosis of AD using frameworks like AT(N). It advocates for a paradigm shift in treatment towards multi-target combination therapies, which could lead to significantly enhanced efficacy compared to current single-target approaches. Furthermore, it champions AI-driven patient stratification and the incorporation of advanced technologies like gene editing for highly personalized and effective therapeutic interventions.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract implicitly notes the 'modest efficacy' of current single-target therapies (e.g., anti-A$Œ≤$ mAbs) as a key limitation in the current AD treatment landscape, which this paper aims to address. As a review and conceptual model, the paper itself does not present new experimental data or clinical trial results to validate its proposed network model or the efficacy of specific combination strategies, which would require future empirical research.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future research should focus on developing and validating multi-target combination therapies against A$Œ≤$, tau, and neuroinflammation. Further refinement and integration of biomarker-based diagnostic frameworks for earlier and more precise disease detection are needed. Leveraging emerging technological platforms such as gene editing, biophysical neuromodulation, and AI for patient stratification will be crucial for developing personalized, preemptive, and biomarker-guided interventions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Neuropharmacology</span>
                    
                    <span class="tag">Diagnostics</span>
                    
                    <span class="tag">Geriatric Medicine</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                    <span class="tag">Biomarker Research</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Alzheimer's disease</span>
                    
                    <span class="tag tag-keyword">amyloid-$Œ≤$</span>
                    
                    <span class="tag tag-keyword">tau pathology</span>
                    
                    <span class="tag tag-keyword">neuroinflammation</span>
                    
                    <span class="tag tag-keyword">combination therapy</span>
                    
                    <span class="tag tag-keyword">multi-target therapy</span>
                    
                    <span class="tag tag-keyword">precision medicine</span>
                    
                    <span class="tag tag-keyword">biomarkers</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Alzheimer's disease (AD) persists as a paramount challenge in neurological research, characterized by the pathological hallmarks of amyloid-$Œ≤$ (A$Œ≤$) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. This review synthesizes the evolving understanding of AD pathogenesis, moving beyond the linear amyloid cascade hypothesis to conceptualize the disease as a cross-talk of intricately interacting pathologies, encompassing A$Œ≤$, tau, and neuroinflammation as the foundation of phase-adapted pathological network model. This evolving pathophysiological understanding parallels a transformation in diagnostic paradigms, where biomarker-based strategies such as the AT(N) framework enable early disease detection during preclinical or prodromal stages. Within this new landscape, while anti-A$Œ≤$ monoclonal antibodies (e.g., lecanemab, donanemab), represent a breakthrough as the first disease-modifying therapies, their modest efficacy underscores the limitation of single-target approaches. Therefore, I explore the compelling rationale for combination therapies that simultaneously target A$Œ≤$ pathology, aberrant tau, and neuroinflammation. Looking forward, I emphasize emerging technological platforms such as gene editing and biophysical neuromodulation in advancing precision medicine. Ultimately, the integration of early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification charts a promising roadmap toward fundamentally altering the trajectory of AD. The future of AD management will be defined by preemptive, biomarker-guided, and personalized combination interventions.
Keywords: Alzheimer's disease, amyloid-$Œ≤$, tau pathology, neuroinflammation, combination therapy, multi-target therapy, precision medicine, biomarkers</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>23 pages</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>